首次出版:最新修訂:March 2009交付方式:特快專遞(2-3天送達(dá))
報(bào)告屬性:共0頁(yè)下載目錄 版權(quán)聲明
定購(gòu)電話:0755-82571522、82571566、400-008-1522
24小時(shí)服務(wù)熱線:138 0270 8576 定制報(bào)告
版本 | 在線版 | 電子版+印刷版 | 在線報(bào)告庫(kù)(超1000份報(bào)告)全庫(kù) |
---|---|---|---|
優(yōu)惠價(jià) | RMB 6800 | RMB 7800 | RMB 9800 |
原價(jià) | RMB 9600 | RMB 9800 | - |
在線報(bào)告庫(kù)有超1000份報(bào)告,
全庫(kù)只需9800元,平均每份報(bào)告僅需9.8元!
聯(lián)系電話: 400 008 0586; 0755-82571568
微信掃碼:
1.EXECUTIVESUMMARY
Overview
·OverviewofEuropeanNon-Hodgkin'sLymphomaTherapeuticsMarket
2.GLOSSARYOFTERMS
ListofTerms
·Abbreviations
3.RESEARCHMETHODOLOGY
ResearchScopeandObjective
·Methodology
4.MARKETOVERVIEW
Introduction
·DiseaseCharacteristics
·Epidemiology
·RiskFactors
·Symptoms
·ClassificationandStaging
·MajorSubTypes
·CurrentTreatmentRegimes
5.INDUSTRYCHALLENGES
IndustryChallengesfortheEuropeanNon-Hodgkin'sLymphomaTherapeuticsMarket
·ChallengesFacedbyPharmaceuticalandBiotechnologyCompanies
6.TOTALEUROPEANMARKETFORNON-HODGKIN'SLYMPHOMATHERAPEUTICSMARKET
MarketDriversandRestraints
·MarketDrivers
·MarketRestraints
·MarketEngineeringMeasurementAnalysis
7.TOTALFORECASTSFORTHEEUROPEANNON-HODGKIN'STHERAPEUTICSMARKET
ForecastsandPipelineAnalysis
·PatientForecasts
·RevenueForecasts
·MarketShareAnalysis
·PipelineAnalysis
8.STRATEGICRECOMMENDATIONSFORTHEEUROPEANNON-HODGKIN'STHERAPEUTICSMARKET
MarketEngineeringRecommendations
·StrategicRecommendations
9.DATABASEOFKEYINDUSTRYPARTICIPANTS
KeyIndustryParticipants
·KeyParticipantsintheNon-Hodgkin'sLymphomaMarket
10.DECISIONSUPPORTDATABASES
DatabasesforAnalysis
·NumberofBiotechnologyCompanies
·PrivateInvestmentinBiotechnology
·GovernmentR&DInvestmentinBiotechnology
·PercentofGovernmentInvestmentinBiotechnology
·NumberofBiotechnologyPatentsFiledatorGrantedbytheEuropeanPatentOffice
·NumberofBiotechnologyPatentsGrantedbytheUSPatent&TrademarkOffice
This research service analyses the European Non-Hodgkin' s Lymphoma therapeutics market. It analyses market drivers, restraints and challenges faced by industry participants. Revenue forecasts and pipeline analysis has been discussed. It also provides strategic recommendations.